BR9806996A - Composição anestésica, e, processos para preparar a mesma e para estabilizar um composto fluoréter anidro possuindo uma porção alfa fluoréter - Google Patents

Composição anestésica, e, processos para preparar a mesma e para estabilizar um composto fluoréter anidro possuindo uma porção alfa fluoréter

Info

Publication number
BR9806996A
BR9806996A BR9806996-9A BR9806996A BR9806996A BR 9806996 A BR9806996 A BR 9806996A BR 9806996 A BR9806996 A BR 9806996A BR 9806996 A BR9806996 A BR 9806996A
Authority
BR
Brazil
Prior art keywords
fluorether
anhydrous
processes
compound
anesthetic composition
Prior art date
Application number
BR9806996-9A
Other languages
English (en)
Inventor
Christopher Bieniarz
Rajagopalan Raghavan
Steve H Chang
Shuyen L Huang
Toshikazu Kawai
Manami Kobayashi
David Loffredo
Earl R Speicher
Keith R Cromack
Honorate A Stelmach
Original Assignee
Abbott Lab
Central Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9806996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Central Glass Co Ltd filed Critical Abbott Lab
Publication of BR9806996A publication Critical patent/BR9806996A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)

Abstract

"COMPOSIçãO ANESTéSICA, E, PROCESSOS PARA PREPARAR A MESMA E PARA ESTABILIZAR UM COMPOSTO FLUORéTER ANIDRO POSSUINDO UMA PORçãO ALFA FLUORéTER". A presente invenção está relacionada a uma composição anestésica contendo um composto fluoréter anidro e um inbidor de ácido de Lewis fisiologicamente aceitável (e.g., água, hidroxigeno butilado, metilparabeno, propofol, timol). Esta composição apresenta uma estabilidade melhorada e não se degrada na presença de um ácido de Lewis.
BR9806996-9A 1997-01-27 1998-01-23 Composição anestésica, e, processos para preparar a mesma e para estabilizar um composto fluoréter anidro possuindo uma porção alfa fluoréter BR9806996A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
PCT/US1998/001376 WO1998032430A1 (en) 1997-01-27 1998-01-23 Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid

Publications (1)

Publication Number Publication Date
BR9806996A true BR9806996A (pt) 2000-03-14

Family

ID=25148366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806996-9A BR9806996A (pt) 1997-01-27 1998-01-23 Composição anestésica, e, processos para preparar a mesma e para estabilizar um composto fluoréter anidro possuindo uma porção alfa fluoréter

Country Status (28)

Country Link
US (6) US5990176A (pt)
EP (2) EP0967975B1 (pt)
JP (5) JP3183520B2 (pt)
KR (1) KR100368672B1 (pt)
CN (3) CN1321958C (pt)
AR (2) AR011090A1 (pt)
AT (2) ATE201987T1 (pt)
AU (1) AU726733B2 (pt)
BG (2) BG109751A (pt)
BR (1) BR9806996A (pt)
CA (2) CA2626424A1 (pt)
CO (1) CO4920220A1 (pt)
CZ (1) CZ297092B6 (pt)
DE (2) DE69833884T2 (pt)
DK (2) DK1114641T3 (pt)
ES (2) ES2170474T3 (pt)
GR (1) GR3036190T3 (pt)
HK (1) HK1074434A1 (pt)
HU (1) HUP0002101A3 (pt)
IL (1) IL130150A (pt)
NO (1) NO993606L (pt)
NZ (1) NZ335994A (pt)
PL (1) PL334477A1 (pt)
PT (2) PT967975E (pt)
SK (1) SK284243B6 (pt)
TR (1) TR199901579T2 (pt)
WO (1) WO1998032430A1 (pt)
ZA (1) ZA98418B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US6162443A (en) 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
JP4198318B2 (ja) * 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
EP1439677B9 (en) 1999-01-08 2007-11-07 Sony Deutschland GmbH Synchronisation symbol structure for an OFDM system
TW523409B (en) * 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
ES2289524T3 (es) * 2003-09-10 2008-02-01 Cristalia Produtos Quimicos Farmaceuticos Ltda. Composicion farmaceutica estable de un compuesto de fluoroeter para uso anestesico, procedimiento para estabilizar un compuesto de fluoroeter, uso de un agente estabilizador para evitar la degradacion de un compuesto de fluoroeter.
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
CN102631335A (zh) * 2005-04-18 2012-08-15 皮拉莫危急护理有限公司 含水量可忽略的七氟烷的制备方法
WO2009049460A1 (fr) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. Nouveau matériau conditionné de sévoflurane
CN107661293A (zh) * 2008-01-22 2018-02-06 得克萨斯大学体系董事会 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物
US20090275785A1 (en) * 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CA2952552C (en) * 2016-11-02 2018-05-15 Central Glass Company, Limited Method for washing sevoflurane storage container and method for storing sevoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) * 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
CA2278133C (en) 2001-06-26
GR3036190T3 (en) 2001-10-31
CN1152674C (zh) 2004-06-09
CN1321958C (zh) 2007-06-20
HUP0002101A3 (en) 2002-03-28
KR100368672B1 (ko) 2003-01-24
JP2005279283A (ja) 2005-10-13
JP2006143742A (ja) 2006-06-08
DE69800928D1 (de) 2001-07-19
JP3664648B2 (ja) 2005-06-29
DE69833884T2 (de) 2006-08-24
CZ297092B6 (cs) 2006-09-13
PT1114641E (pt) 2006-05-31
NO993606L (no) 1999-09-24
DK0967975T3 (da) 2001-09-17
ATE320798T1 (de) 2006-04-15
BG65414B1 (bg) 2008-07-31
US6677492B2 (en) 2004-01-13
JP3183520B2 (ja) 2001-07-09
AR057610A2 (es) 2007-12-05
EP0967975B1 (en) 2001-06-13
DK1114641T3 (da) 2006-05-15
ATE201987T1 (de) 2001-06-15
NZ335994A (en) 2000-08-25
AR011090A1 (es) 2000-08-02
HK1074434A1 (en) 2005-11-11
EP1114641A3 (en) 2003-05-28
EP1114641A2 (en) 2001-07-11
US20040048932A1 (en) 2004-03-11
US6444859B2 (en) 2002-09-03
WO1998032430A1 (en) 1998-07-30
CA2626424A1 (en) 1998-07-30
US6288127B1 (en) 2001-09-11
US20020016373A1 (en) 2002-02-07
JP2000510159A (ja) 2000-08-08
US20060148906A1 (en) 2006-07-06
ZA98418B (en) 1999-04-20
ES2256104T3 (es) 2006-07-16
DE69800928T2 (de) 2001-11-22
EP1114641B1 (en) 2006-03-22
JP2001187729A (ja) 2001-07-10
BG103656A (en) 2000-04-28
PL334477A1 (en) 2000-02-28
IL130150A (en) 2004-09-27
AU726733B2 (en) 2000-11-16
CN1899271A (zh) 2007-01-24
IL130150A0 (en) 2001-03-19
HUP0002101A2 (hu) 2001-05-28
TR199901579T2 (xx) 1999-12-21
CN1244797A (zh) 2000-02-16
CA2278133A1 (en) 1998-07-30
EP0967975A1 (en) 2000-01-05
DE69833884D1 (de) 2006-05-11
KR20000070482A (ko) 2000-11-25
NO993606D0 (no) 1999-07-23
BG109751A (bg) 2008-06-30
US20030130359A1 (en) 2003-07-10
CO4920220A1 (es) 2000-05-29
US5990176A (en) 1999-11-23
CZ256199A3 (cs) 1999-11-17
AU5930098A (en) 1998-08-18
CN1560003A (zh) 2005-01-05
SK86199A3 (en) 2000-06-12
PT967975E (pt) 2001-11-30
SK284243B6 (sk) 2004-12-01
JP2006137769A (ja) 2006-06-01
ES2170474T3 (es) 2002-08-01

Similar Documents

Publication Publication Date Title
BR9806996A (pt) Composição anestésica, e, processos para preparar a mesma e para estabilizar um composto fluoréter anidro possuindo uma porção alfa fluoréter
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
LU88670I2 (fr) Fluvastatine eventuellement sous forme de sel par exemple sel de sodium
BR9707064A (pt) Novos derivados 19-nor-pregneno
ES2083123T3 (es) Nuevos derivados de aril-etil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
GR1000392B (el) Σταθεροποιημενες συνθεσεις περιεχουσες επιδερμικο παραγοντα αναπτυξης.
BR9913959A (pt) Composição de poliéster e processo de preparação de uma composição de poliéster
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
ID27178A (id) Senyawa aminosikloheksil eter dan penggunaannya
ES2194679T3 (es) Composiciones cosmeticas que contienen creatina, carnitina y/o acido piruvico.
MY123908A (en) Meta-azacyclic amino benzoic acid compounds and derivatives thereof
CO4960655A1 (es) Nueva composicion y su uso
HUP0002117A2 (hu) Érzéstelenítő vegyület átlátszó, injektálható összetételben
AR038658A1 (es) Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
ES2118988T3 (es) Derivados n-sustituidos de n-metil-3-(p-trifluoro-metil-fenoxi)-3-fenil-propil-amina y el procedimiento para su preparacion.
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
PT1206248E (pt) Composicoes sedativo-hipnoticas de libertacao controlada e metodos relacionados com os mesmos
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos
AR008695A1 (es) Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones.
PT82547B (pt) Processo de preparacao de acidos hexenoicos e de composicoes farmaceuticas que os contem
DE69200365D1 (de) Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria.
ES555242A0 (es) Un procedimiento para la preparacion de nuevas 3-alcoxi-2-(n-pirrolidino)-n-piridil-n-furilmetilpropilaminas
BR9907166A (pt) Composição farmacêutica e processo para estabilizar um composto possuindo um grupo éster opcional e um grupo à base de amidina
DE69405999T2 (de) Pharmazeutisch wirksame enantiomere
ATE248805T1 (de) Nicht-hygroskopische salze des l-karnitines und der alkanoyl-karnitine enthaltende feste zusammensetzungen zur oralen verabreichung

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.001702/09 ORIGEM: JUIZO DA 035A VF PREVIDENCIARIA DO RIO DE JANEIRO PROCESSO NO 2009.51.01.805669-7 ACAO ORDINARIA DE NULIDADE DA PATENTE AUTOR: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL E CENTRAL GLASS COMPANY LTD E ABBOTT LABORATORIES.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.001702/09 ORIGEM: 35A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: 2009.51.01.805669-7 MANDADO DE CITACAO AUTOR: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA REU: CENTRAL GLASS COMPANY LTDA, ABBOTT LABORATORIES E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI. DECISAO: PELO EXPOSTO, CONCEDO A ANTECIPACAO DE TUTELA PARA SUSPENDER OS EFEITOS DA PI9806996-9 E, COM BASE NO ART. 269, I, DO CPC, JULGO PROCEDENTE O PEDIDO DE NULIDADE ATO ADMINISTRATIVO DO INPI QUE CONCEDEU A PATENTE PI9806996-9, DE TITULARIDADE DA 2A E 3A RES (ANTECIPADA PELA EP 0701985), EIS QUE DESTITUIDA DOS REQUISITOS DE NOVIDADE E ATIVIDADE INVENTIVA E, AINDA, POR INSUFICIENCIA DESCRITIVA.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.001702/09 2A VARA CIVEL DO FORO REGIONAL XI-PINHEIROS PROCESSO NO:0103252-45.2007.8.26.0011 AUTOR: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA REU: INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIA - INPI/ABBOTT LABORATORIES E OUTROS DECISAO: CONCEDO A ANTECIPACAO DE TUTELA PARA SUSPENDER OS EFEITOS DA PI 9806996-9 E COM BASE NO ART.269,IDO CPC,JULGO PROCEDENTE O PEDIDO DE NULIDADE ATO ADMINISTRATIVO DO INPI QUE CONCEDEU A PATENTE PI 9806996-9,DE TITULARIDADE 2A E 3A RES (ANTECIPADA PELA EP 0701985),EIS QUE DESTITUIDA DOS REQUISITOS DE NOVIDADE E ATIVIDADE INVENTIVA E, AINDA POR INSUFICIENCIA DESCRITIVA .